CCA
CLDX icon

Catalyst Capital Advisors’s Celldex Therapeutics CLDX Stock Holding History

Catalyst Capital Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-417
Closed -$114K – 457
2014
Q4 		$114K Buy
+417
New +$104K 0.01% 314

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Catalyst Capital Advisors's CLDX Position: Q1 2015 in Review

Catalyst Capital Advisors sold out of Celldex Therapeutics (CLDX) in Q1 2015, closing a stake of 417 shares — an estimated $114K sold.

Catalyst Capital Advisors first reported a position in CLDX in Q4 2014 and held it in 1 quarter. The position peaked at $114K in Q4 2014. 193 funds tracked by Wall St. Rank hold CLDX as of Q1 2015.

  • Catalyst Capital Advisors reported no remaining Celldex Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Catalyst Capital Advisors sold 417 Celldex Therapeutics shares in Q1 2015, an estimated $114K.
  • Catalyst Capital Advisors first reported a position in Celldex Therapeutics in Q4 2014 and held it in 1 quarter.
  • Catalyst Capital Advisors's Celldex Therapeutics position peaked at $114K in Q4 2014.
  • 193 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2015.

Based on Catalyst Capital Advisors's 13F filing for Q1 2015, filed 15 May 2015.